Comparing standard vs. longer chemo before pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with borderline or locally advanced pancreatic cancer.
- You are in good enough health to tolerate chemotherapy (ECOG score 0 or 1).
- You have not had chemotherapy for pancreatic cancer in the last 5 years.
- You have adequate blood counts and liver/kidney function.
- You are not pregnant or nursing, and use reliable birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.